2016
DOI: 10.1038/ncomms12211
|View full text |Cite
|
Sign up to set email alerts
|

Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care

Abstract: Current biopharmaceutical manufacturing systems are not compatible with portable or distributed production of biologics, as they typically require the development of single biologic-producing cell lines followed by their cultivation at very large scales. Therefore, it remains challenging to treat patients in short time frames, especially in remote locations with limited infrastructure. To overcome these barriers, we developed a platform using genetically engineered Pichia pastoris strains designed to secrete m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
79
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 77 publications
(79 citation statements)
references
References 41 publications
0
79
0
Order By: Relevance
“…As the applications of metabolic engineering expand beyond traditional chemical production, tight control of output in response to the external environment will be necessary. Cells are already being engineered to specifically deliver drugs to tumors (Forbes 2010, Din et al 2016, Hosseinidoust et al 2016) and to produce different drugs based on what is needed in low-resource settings (Choi et al 2014, Perez-Pinera et al 2016). For both of these applications, it is necessary that cells produce the desired compound only in the desired condition—specificity of response based on environment is critical.…”
Section: Discussionmentioning
confidence: 99%
“…As the applications of metabolic engineering expand beyond traditional chemical production, tight control of output in response to the external environment will be necessary. Cells are already being engineered to specifically deliver drugs to tumors (Forbes 2010, Din et al 2016, Hosseinidoust et al 2016) and to produce different drugs based on what is needed in low-resource settings (Choi et al 2014, Perez-Pinera et al 2016). For both of these applications, it is necessary that cells produce the desired compound only in the desired condition—specificity of response based on environment is critical.…”
Section: Discussionmentioning
confidence: 99%
“…If enzyme or promoter variants are being compared for expression levels, picking outliers from a population may strongly bias the results, leading to an unclear assessment of the effect of the enzyme or promoter variations. To rule out these effects, two strategies appear feasible: (i) confirming specific integration (by demonstrating growth phenotypes, by colony PCR, or by using site-specific molecular "landing pad" recombination systems [55]) or (ii) screening a sufficient number of transformants to obtain a representative population distribution and thus avoid outliers.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, biomolecular machines capable of dynamic probing and decision‐making in situ could offer new ways to interface biology (Slomovic et al , ; Courbet et al , ) as well as unprecedented versatility in analytical and biomedical applications. For instance, synthetic cell‐based devices can be designed and employed as programmable bioanalytical tools to detect molecular cues for diagnostic purposes (Courbet et al , ; Danino et al , ) or smart therapeutics (Ye & Fussenegger, ; Perez‐Pinera et al , ; Roybal et al , ; Xie et al , ).…”
Section: Introductionmentioning
confidence: 99%